The abstract is read at the publisher; the summary is JClub's.
Higher circulating immune-surveillance–related proteins, especially those tied to natural killer and T cell activity, are linked to lower prostate cancer risk in EPIC.
- Why it matters: Tumour inflammation and immune evasion are central to cancer, yet prospective evidence connecting specific immune pathways to prostate cancer risk has been limited.
- What they did: The study measured 368 immune- and inflammation-related proteins in EPIC (1434 cases with matched controls) and combined results with UK Biobank; meta-analysis highlighted IL15 and FLT3LG, particularly in blood drawn long before diagnosis.
- The result: Genetic analyses implicated PARP1, SPINT2, and NME3 in increased risk, supporting immune pathways as contributors and pointing to potential prevention targets.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.